James J Beaudoin

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 9

Top Topics

Polycystic Kidney Disease

Ultra High Performance Liquid Chromatography

Electronic Health Record

Top Venues

Drug metabolism and disposition: the biological fate of chemicals

Clinical pharmacology and therapeutics

Alcoholism, clinical and experimental research

Hepatology communications

This page only lists publications with an associated author ORCID identifier.

Publications

James J Beaudoin, Lara Clemens, Mark T Miedel, Albert Gough, Fatima Zaidi, Priya Ramamoorthy, Kari E Wong, Rangaprasad Sarangarajan, Christina Battista, Lisl K M Shoda, Scott Q Siler, D Lansing Taylor, Brett A Howell, Lawrence A Vernetti, Kyunghee Yang
The Combination of a Human Biomimetic Liver Microphysiology System with BIOLOGXsym, a Quantitative Systems Toxicology (QST) Modeling Platform for Macromolecules, Provides Mechanistic Understanding of Tocilizumab- and GGF2-Induced Liver Injury. International journal of molecular sciences 24 (11) (2023)
William A Murphy, Jeffry Adiwidjaja, Noora Sjöstedt, Kyunghee Yang, James J Beaudoin, Jessica Spires, Scott Q Siler, Sibylle Neuhoff, Kim L R Brouwer
Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH). Clinical pharmacology and therapeutics (2022)
William A Murphy, James J Beaudoin, Tuomo Laitinen, Noora Sjöstedt, Melina M Malinen, Henry Ho, Peter W Swaan, Paavo Honkakoski, Kim L R Brouwer
Identification of Key Amino Acids that Impact Organic Solute Transporter α/β (OSTα/β). Molecular pharmacology 100 (6) (2021)
James J Beaudoin, Tiebing Liang, Qing Tang, Bubu A Banini, Vijay H Shah, Arun J Sanyal, Naga P Chalasani, Samer Gawrieh
Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis. Alcoholism, clinical and experimental research 45 (4) (2021)
James J Beaudoin, William J Brock, Paul B Watkins, Kim L R Brouwer
Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity. Clinical pharmacology and therapeutics 109 (2) (2020)
William J Brock, James J Beaudoin, Jason R Slizgi, Mingming Su, Wei Jia, Sharin E Roth, Kim L R Brouwer
Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. International journal of toxicology 37 (2) (2019)
Jacqueline Bezençon, James J Beaudoin, Katsuaki Ito, Dong Fu, Sharin E Roth, William J Brock, Kim L R Brouwer
Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease. Drug metabolism and disposition: the biological fate of chemicals 47 (8) (2019)
James J Beaudoin, Jacqueline Bezençon, Yanguang Cao, Katsuhiko Mizuno, Sharin E Roth, William J Brock, Kim L R Brouwer
Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. Drug metabolism and disposition: the biological fate of chemicals 47 (2) (2018)
Suthat Liangpunsakul, James J Beaudoin, Vijay H Shah, Puneet Puri, Arun J Sanyal, Patrick S Kamath, Spencer G Lourens, Qing Tang, Barry P Katz, David W Crabb, Naga P Chalasani
Interaction between the patatin-like phospholipase domain-containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis. Hepatology communications 2 (1) (2017)